GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Pharmalabs Ltd (NSE:AARTIPHARM) » Definitions » Inventories, Finished Goods

Aarti Pharmalabs (NSE:AARTIPHARM) Inventories, Finished Goods : ₹0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Aarti Pharmalabs Inventories, Finished Goods?

Aarti Pharmalabs's annual finished goods increased from Mar. 2022 (₹1,902 Mil) to Mar. 2023 (₹2,653 Mil) and increased from Mar. 2023 (₹2,653 Mil) to Mar. 2024 (₹2,966 Mil).


Aarti Pharmalabs Inventories, Finished Goods Historical Data

The historical data trend for Aarti Pharmalabs's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Pharmalabs Inventories, Finished Goods Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Inventories, Finished Goods
- 1,902.18 2,653.11 2,966.47

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,966.47 - - -

Aarti Pharmalabs Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Aarti Pharmalabs Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 2nd floor, 204, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.

Aarti Pharmalabs Headlines

No Headlines